Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China.

Lesher B, Gao X, Chen Y, Liu Z.

Clinicoecon Outcomes Res. 2016 Mar 24;8:63-72. doi: 10.2147/CEOR.S91985. eCollection 2016. Review.

2.

Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial.

Li HK, Scarborough M, Zambellas R, Cooper C, Rombach I, Walker AS, Lipsky BA, Briggs A, Seaton A, Atkins B, Woodhouse A, Berendt A, Byren I, Angus B, Pandit H, Stubbs D, McNally M, Thwaites G, Bejon P.

Trials. 2015 Dec 21;16:583. doi: 10.1186/s13063-015-1098-y.

3.

Role of Interleukin-12 in Protection against Pulmonary Infection with Methicillin-Resistant Staphylococcus aureus.

Nguyen QT, Furuya Y, Roberts S, Metzger DW.

Antimicrob Agents Chemother. 2015 Oct;59(10):6308-16. doi: 10.1128/AAC.00968-15. Epub 2015 Jul 27.

4.

Improving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy.

Blumenthal KG, Parker RA, Shenoy ES, Walensky RP.

Clin Infect Dis. 2015 Sep 1;61(5):741-9. doi: 10.1093/cid/civ394. Epub 2015 May 19.

PMID:
25991471
5.

Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.

Cates JE, Mitrani-Gold FS, Li G, Mundy LM.

Antimicrob Agents Chemother. 2015 Aug;59(8):4510-20. doi: 10.1128/AAC.00679-15. Epub 2015 May 18.

6.

Proportions of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in patients with surgical site infections in mainland China: a systematic review and meta-analysis.

Yang Z, Wang J, Wang W, Zhang Y, Han L, Zhang Y, Nie X, Zhan S.

PLoS One. 2015 Jan 20;10(1):e0116079. doi: 10.1371/journal.pone.0116079. eCollection 2015. Review.

7.

Rising Methicillin-Resistant Staphylococcus aureus Infections in Ear, Nose, and Throat Diseases.

Thirumazhisi Sachithanandam S.

Case Rep Otolaryngol. 2014;2014:253945. doi: 10.1155/2014/253945. Epub 2014 Nov 6.

8.

Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model.

Hilliard JJ, Datta V, Tkaczyk C, Hamilton M, Sadowska A, Jones-Nelson O, O'Day T, Weiss WJ, Szarka S, Nguyen V, Prokai L, Suzich J, Stover CK, Sellman BR.

Antimicrob Agents Chemother. 2015 Jan;59(1):299-309. doi: 10.1128/AAC.03918-14. Epub 2014 Oct 27.

9.

Community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia without evidence of antecedent viral upper respiratory infection.

Toro CM, Janvier J, Zhang K, Fonseca K, Gregson D, Church D, Laupland K, Rabin H, Elsayed S, Conly J.

Can J Infect Dis Med Microbiol. 2014 May;25(3):e76-82.

10.

Antibiotic Resistance Profiling of Staphylococcus aureus Isolated from Clinical Specimens in a Tertiary Hospital from 2010 to 2012.

Juayang AC, de Los Reyes GB, de la Rama AJ, Gallega CT.

Interdiscip Perspect Infect Dis. 2014;2014:898457. doi: 10.1155/2014/898457. Epub 2014 Sep 3.

11.
12.

Unexpected Multidrug Resistance of Methicillin-Resistant Staphylococcus aureus in Urine Samples: A Single-Center Study.

Lunacek A, Koenig U, Mrstik C, Radmayr C, Horninger W, Plas E.

Korean J Urol. 2014 May;55(5):349-53. doi: 10.4111/kju.2014.55.5.349. Epub 2014 May 12.

13.
14.
15.

The giant protein Ebh is a determinant of Staphylococcus aureus cell size and complement resistance.

Cheng AG, Missiakas D, Schneewind O.

J Bacteriol. 2014 Mar;196(5):971-81. doi: 10.1128/JB.01366-13. Epub 2013 Dec 20.

16.

Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States.

Mendes RE, Flamm RK, Hogan PA, Ross JE, Jones RN.

Antimicrob Agents Chemother. 2014;58(2):1243-7. doi: 10.1128/AAC.02112-13. Epub 2013 Dec 9.

17.

Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis.

Kalil AC, Klompas M, Haynatzki G, Rupp ME.

BMJ Open. 2013 Oct 14;3(10):e003912. doi: 10.1136/bmjopen-2013-003912.

18.

Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia.

Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF.

J Infect Dis. 2013 Jul;208(1):75-82. doi: 10.1093/infdis/jit129. Epub 2013 Mar 26.

19.

Community-Associated Methicillin-Resistant Staphylococcus aureus Lacking PVL, as a Cause of Severe Invasive Infection Treated with Linezolid.

Gouveia C, Gavino A, Bouchami O, Miragaia M, Varandas L, de Lencastre H, Brito MJ.

Case Rep Pediatr. 2013;2013:727824. doi: 10.1155/2013/727824. Epub 2013 Feb 20.

20.

The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections.

Fu J, Ye X, Chen C, Chen S.

PLoS One. 2013;8(3):e58240. doi: 10.1371/journal.pone.0058240. Epub 2013 Mar 6.

Items per page

Supplemental Content

Write to the Help Desk